

# Screening for latent tuberculosis infection using IGRA in destitute refugees and asylum seekers

Dr Shazia Munir GP/Clinical Lead Health Inclusion Clinic, GSTT

Dr Judith Eling Specialist Trainee in Public Health Lambeth Local Authority



# Content

- Background: Health inclusion clinic, Tuberculosis, Latent TB
- Aims
- Methods
- Results
- Problems faced
- Conclusions

#### **Health Inclusion Clinic**

#### Guy's and St Thomas'

NHS Foundation Trust NHS









- 30 minute appointment
- Telephone or face to face interpreter
- Medico-legal reports and other letters provided free of charge



### Health Inclusion Clinic

- Blood borne viruses, STI
- Latent TB (IGRA)
- Diabetes

Refugee

screen

Case

working

Extended GP

appointment

- Parasites (eosinophilia)
- Anaemia
- Vitamin D
- Catch-up immunisations

- Interpreting and translating
- Liaison with secondary care
- Liaison with solicitors etc.
- Escorting to appointments

# Tuberculosis

- Mycobacterium tuberculosis
- Most commonly affects lungs
- Can infect any part of body
- Droplet spread
- One of the top 10 causes of death worldwide<sup>1</sup>



## **Tuberculosis rates in England**



- London highest rate of TB in England
- Year-on-year decline in London (35% reduction) and England over past 4 years<sup>2</sup>

# Three-year average TB rates by local authority district, England, 2013-2015<sup>2</sup>

<u></u>



Tuberculosis rate (per 100,000)





# **Risk Factors for Acquiring TB**

- Socioeconomic deprivation
- Country of birth
- Social risk factors: Homelessness, drug and alcohol misuse, prison
- People with social risk factors more likely to have drug resistance and worse TB outcomes

# Refugees and asylum seekers particularly at risk

#### TB case notifications and rates by place of birth, England, 2000-2015<sup>2</sup>



# Latent TB Infection (LTBI)

- Asymptomatic and not infectious
- Risk of progression to active TB 5-12%<sup>3</sup>
- Treatment for LTBI:
  - 3 months combination therapy or
  - 6 months isoniazid
- Lifetime risk of developing active TB after completing treatment for latent TB reduced by 60%<sup>4</sup>

# Testing for Latent TB

#### 1. Tuberculin skin test

- low specificity and sensitivity
- observer bias
- follow up in 2-3 days
- 2. IGRA (Interferon Gamma Release Assay)
  - single blood test
  - T-SPOT, Quantiferon Gold
  - NICE TB guidelines<sup>5</sup>





### **Previous studies**

- 2009 Sheffield, refugee population<sup>6</sup>
   25% positive IGRA
- 2014-15 Newham, screening offered to people from very high prevalence countries<sup>7</sup>
   – 26% positive IGRA
- 2015 -16 Analysis of national screening pilots for first year<sup>2</sup>
  - 25% positive IGRA

### Aims

In our clinic population:

- To measure the prevalence of latent TB
- To assess the practicalities of IGRA testing

# Method

- Nov 2014 Nov 2015
- Opportunistic IGRA screening
  - >16 years old
  - Previous/current TB and HIV excluded
- T-SPOT<sup>®</sup>
- Counselling by nurse/doctor

# Method

- Positive IGRA referred to TB clinic
- Decision on whether to offer chemoprophylaxis based on individual patient
  - Co-morbidities
  - 2011 NICE Guidelines <35 years old<sup>5</sup>
  - 2016 NICE Guidelines <65 years old<sup>8</sup>

### Results



#### **IGRA** results



#### **IGRA** Positive



### Analysis: demographics

	Positive IGRA (28)	Negative IGRA (54)
Male	19 (68%)	34 (63%)
Female	9 (32%)	20 (37%)
Age (range)	22-59	21-63
Age (median)	40	35.5
Age < 35	14 (50%)	27 (50%)
Age 35-64	14 (50%)	27 (50%)

### Analysis: risk factors

Risk factor	Positive IGRA (28)	Negative IGRA (54)
Chronic disease	13 (46%)	18 (33%)
Alcohol or drug misuse	4 (14%)	4 (7%)
Country of origin rate of TB:		
very high (>150/100,000)	17 (61%)*	19 (35%)
high (40 to 150/100,000)	11 (39%)	25 (46%)
low (<40/100,000)	0 (0%)	10 (19%)

\* x<sup>2</sup> = 4.85 p < 0.05

# **Country of Origin**



Country of origin incidence rate of TB

#### Accommodation



#### Numbers needed to screen

 3.28 individuals need to be screened to find 1 case of latent TB

 50.5 - 101 individuals need to be screened and treated in order to prevent 1 case of active TB

# **Problems faced**

- Lost to follow up, appointment letters not received, DNAs
- Laboratory problems
  - T-SPOT samples need to be received by lab
    <36 hours</li>
- Side effects of chemoprophylaxis?
- Stigma of diagnosis
- Patient anxiety

# Moving forward

- Good communication with TB clinic
- Referral process now via email
- Sample collection system
- Consider Quantiferon Gold?
- Patient education and counselling

# **Summary of Findings**

- IGRA highly acceptable to patients only 2 declined testing
- 33% positive IGRA
- 50.5 101 individuals need to be screened and treated in order to prevent 1 case of active TB

#### **IGRA:** Potential benefits?

Cost effective?

 Public health benefit



#### Proportion of pulmonary TB cases with a delay from symptom onset to treatment start by place of birth, England, 2011-2015<sup>1</sup>



>2 months delay >4 months delay





developed in collaboration with and with partner funding from **NHS England** 

#### Access, testing and treatment

#### A toolkit for new entrant latent tuberculosis programmes



 GPs registered, new entrants <5 years in UK, very high incidence country of origin, 16-35 years old

# Conclusions

- Highly acceptable test
- High latent TB rate in destitute refugee and asylum seeker population
- Importance of communication, counselling and follow up

#### Any questions?



# References

- 1. WHO, TB Factsheet, October 2016, available online on http://www.who.int/mediacentre/factsheets/fs104/en/
- 2. Public Health England. Tuberculosis in England, 2016 report, [internet] available on <u>https://www.gov.uk/government/uploads/system/uploads/attachment\_data/file/581238/TB\_Annu</u> <u>al\_Report\_2016\_GTW2309\_errata\_v1.2.pdf</u>
- 3. Hauck, F., & Neese, B. (2009). Identification and Management of Latent Tuberculosis Infection. *American Family Physician*, 879-886.
- 4. Jimenez-Fuentes , M., de Souza-Galvao, M., & et al. (2013). Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. *International Journal of Tuberculosis and Lung Disease*, 326-32.
- 5. NICE, "Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control," NICE, London, 2011.
- 6. A. Tunbridge, *Personal communication*.
- 7. M. Burman, G. P. J. Ahmed, V. White, N. Jayasekera and H. Kunst, "S39 Preliminary Results of a Latent Tuberculosis Screening and Treatment Project and the Role of TB Services in Secondary Care," *Thorax*, vol. 70, no. Suppl 3, 2015.
- 8. NICE, "Tuberculosis-fuil guideline (Internet).," 2016. [Online]. Available: <u>https://www.nice.org.uk/guidance/ng33/chapter/recommendations#diagnosing-latent-tb-in-all-age-groups</u>
- 9. TB Alert, "Access, testing and treatment. A toolkit for new entrant latent tuberculosis programmes," TB Alert, London, 2016.

# Acknowledgements

- Dr Polly Nyiri, Dr Uzma Mahmood, Yvonne Keene, Rachel Smith – Health Inclusion Clinic
- Carmen Rojas Service Lead, Three Boroughs
- Dr Ronan Breen Consultant Respiratory Physician, Guy's & St Thomas' Hospital Trust
- Dr Felicity Perrin Consultant Respiratory Physician, Kings College Hospital
- Margaret Ogedengbe Community TB Nurse

# Risk factors for reactivation of TB<sup>8</sup>

- HIV-positive
- younger than 5 years
- excessive alcohol intake
- injecting drug users
- solid organ transplantation
- haematological malignancy
- having chemotherapy
- have had a jejunoileal bypass
- diabetes
- chronic kidney disease or receive haemodialysis
- have had a gastrectomy
- are having treatment with anti-tumour necrosis factor-alpha or other biologic agents
- silicosis

#### Proportion testing positive according to duration of living in UK

